Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2018

View Archived Issues

Cutting carb clutter could transform diabetes treatment

Patient enrollment ongoing in phase I study of EHP-101

Oncorus nominates lead clinical candidate

FF-10850, a novel liposomal topotecan with improved preclinical PK, safety and antitumor effects

Morphogen-IX names clinical candidate for PAH

miR 1249-5p identified as novel biomarker in NASH

New palbociclib-resistant luminal A breast cancer PDX model from a clinically resistant patient

New animal models of prostate cancer designed for immuno-oncology research

Relafalk approved by the European decentralized procedure for treatment of travelers' diarrhea

Pulmocide initiates phase II study of PC-945

BDP-9066 significantly increases survival and prevents radiation-induced infiltration of GBM in vivo

Phase I results reported for EBV-specific T-cell therapy in progressive multiple sclerosis

Takeda describes new BRD4 BD2 domain inhibitors

Transitional endoplasmic reticulum ATPase inhibitors identified at the University of Pittsburgh

Positive preliminary phase I data presented for TransCon CNP

The Warner Babcock Institute for Green Chemistry patents beta-amyloid inhibitors

Genetics of ADHD correlates with health risk behavior

KCNQ2/3 channel activators patented by Knopp Biosciences

Forge Therapeutics presents bacterial lpxC inhibitors

Phase III clinical study of Fycompa monotherapy meets primary endpoint

Takhzyro subcutaneous injection approved in Europe for the preventive treatment of HAE

Precedex approved for use in pediatric patients in Japan

Positive topline data presented from ENLIGHTEN-2 phase III study of ALKS-3831

Positive phase II data presented, initiation of phase III pemphigus program announced for PRN-1008

First patient enrolled in phase III study of JZP-258 for the treatment of idiopathic hypersomnia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...